Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole

Volume: 67, Issue: 5, Pages: 508 - 515
Published: Sep 1, 2021
Abstract
• Brain edema is a common problem during the course of glioblastoma. • Brain edema often requires treatment on its own, separate from specific anti-tumor treatments. • Current first-line treatment is dexamethasone or a related corticosteroid. • Use of dexamethasone or related corticosteroid shortens survival. • Three old drugs - the diuretic spironolactone, the anti-bradykinin drug ecallantide, and the antifungal drug clotrimazole each have...
Paper Details
Title
Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: Spironolactone, ecallantide, clotrimazole
Published Date
Sep 1, 2021
Volume
67
Issue
5
Pages
508 - 515
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.